Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Ethical, Behavioral, and Social Aspects of HIV Vaccine Trials in Developing Countries
JAMA: The Journal of the American Medical Association, Volume 271, No. 4, Year 1994
Notification
URL copied to clipboard!
Description
Several investigators are preparing to conduct efficacy trials of human immunodeficiency virus (HIV) vaccines in the developing world. Failure to adequately address the unique ethical, behavioral, and social issues that surround vaccine testing in that setting will jeopardize the success of these trials and future acquired immunodeficiency syndrome (AIDS) research in the host nation. —Twelve investigators from Africa, Asia, North America, and South America reviewed previous experience with HIV trials in developing countries and explored potential solutions to these issues. —Host country scientists, government officials, and media must be actively involved in all aspects of the trials. Minimum prerequisites for conducting the trial include the following: (1) researching vaccines active against developing world HIV isolates; (2) establishing and maintaining an adequate technological infrastructure; (3) assessing the feasibility of recruitment in countries where the existence of HIV may be denied; (4) designing methods to obtain informed consent from each individual subject, rather than exclusively from family members or community elders; (5) creating locally appropriate instruments to measure risk behavior; (6) identifying a behavioral intervention for placebo and treatment groups; (7) making available laboratory methods to distinguish between natural HIV infection and vaccine-induced seropositivity; and (8) guaranteeing that an effective vaccine is available free of charge to the placebo group and at affordable prices to other host country residents. © 1994, American Medical Association. All rights reserved.
Authors & Co-Authors
Lurie, Peter G.
United States, San Francisco
University of California, San Francisco
Bishaw, Makonnen
United States, San Francisco
University of California, San Francisco
Chesney, Margaret A.
United States, San Francisco
University of California, San Francisco
Hearst, Norman G.
United States, San Francisco
University of California, San Francisco
Katongole-Mbidde, Edward
United States, San Francisco
University of California, San Francisco
Koetsawang, Suporn
United States, San Francisco
University of California, San Francisco
Lindan, Christina P.
United States, San Francisco
University of California, San Francisco
Mandel, Jeffrey S.
United States, San Francisco
University of California, San Francisco
Mhloyi, Marvellous M.
United States, San Francisco
University of California, San Francisco
Coates, Thomas J.
United States, San Francisco
University of California, San Francisco
Statistics
Citations: 67
Authors: 10
Affiliations: 1
Identifiers
Doi:
10.1001/jama.1994.03510280057033
ISSN:
00987484
Research Areas
Infectious Diseases
Study Design
Randomised Control Trial